| INTRODUCTION
Colorectal cancer (CRC) is the third most prevalent cancer and the third leading cause of cancer-related death worldwide. 1 The carcinogenesis of CRC is a multi-step process which is characterized by genomic alterations. 2 It is more frequent in the industrialized countries adopting western lifestyle and dietary habits, than in developing countries. Despite the great advance in overall survival, prognosis of CRC is highly dependent on the stage at diagnosis. The 5-year survival rates range from 90% for stage I to 10% for stage IV. However, approximately 30% of patients show distant metastases at diagnosis. 1 Therefore, early detection and diagnosis of CRC positively correlates with substantial improvements in survival. Several clinical tests are considered as the powerful tools for reduction of cancerrelated incidence and mortality, including endoscopy, fecal occult blood tests (FOBT), and radiology tests. 3 Therefore, it is crucial to identify a novel and noninvasive biomarker for the early diagnosis of CRC.
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High mobility group AT-hook 2 belongs to a family of nonhistone chromatin-binding proteins which regulate the process of transcription by altering the structure of chromatin. 4 It is absent in normal human adult tissues, but abundantly expressed in many human malignancies, such as lung, ovarian, breast, pancreatic, and colorectal cancer. As an oncoprotein, it influences a variety of biologic processes, including cell proliferation, apoptosis, differentiation, embryogenesis, and metastasis.
5
Previous studies have focused on endoscopic examination and histological evaluation of tumor specimens obtained by biopsy or surgical resection for CRC diagnosis. However, the above methods are either insufficient or invasive. Although serum carcinoembryonic antigen (CEA) and CA199 are the most widely used blood biomarkers for diagnosing CRC, 6,7 lack of sufficient sensitivity and specificity limit the extensive application. To find new tools for the early diagnosis of CRC, expressions of circulating cell-free HMGA2 mRNA were detected in the plasma of patients and healthy controls, and relationships with clinicopathologic characteristics were also analyzed.
In this study, we evaluated the plasma mRNA levels of HMGA2 in 83 CRC patients and 11 normal controls. Our analyses showed that circulating cell-free HMGA2 mRNA was significantly elevated in the plasma of CRC patients. High levels of HMGA2 were associated with tumor location, positive nerve infiltration, positive vascular invasion, negative microsatellite instability (MSI) status, and elevated serum CA199 levels. All of these results demonstrated that HMGA2 mRNA from plasma could be used as a potential marker for diagnosis in CRC.
| MATERIALS AND METHODS

| Patients and samples
In all, 83 CRC patients who underwent surgery at the Second Affiliated
Hospital of Zhejiang University and 11 healthy donors were enrolled in this study. Tissues and plasma specimens were obtained at the time of surgery. The clinicopathologic parameters of these cases are summarized in Table 1 . This study was approved by the Ethical Committee of Zhejiang University.
| RNA extraction from plasma
RNA was extracted using QIAamp Circulating Nucleic Acid kit (Qiagen, 
| Real-time quantitative reverse transcription-PCR
cDNA was synthesized from RNA (100 ng) using the High Capacity cDNA Reverse Transcription Kit (Thermo Fisher, Shanghai, China) according to instructions provided by the manufacturer. Then, real-time PCR assays were performed by SYBR Green PCR Master Mix (Applied Biosystems, Shanghai, China) using an ABI Prism 7900
Detection System. The primers used in this study were as follows:
HMGA2 forward 5′-ATCTACTACCAAGAACCA-3′, HMGA2 reverse 5′-ACACATAAGGCTCATAGA-3′, GAPDH forward 5′-CCCTTCATTG ACCTCAACTACATG-3′, GAPDH reverse 5′-TGGGATTTCCATTGATG ACAAGC-3′.
| Statistical analyses
Statistical analyses were conducted by SPSS version 22.0 software. The results were expressed as mean ± standard deviation and analyzed by Student's t test or one-way ANOVA. P < .05 was considered as statistically significant. To determine the performance of plasma HMGA2 mRNA in diagnosing CRC, receiver operating characteristic (ROC) curve was plotted and the corresponding area under the curve (AUC) was analyzed.
| RESULTS
| Circulating HMGA2 mRNA served as a potential biomarker for CRC diagnosis
Circulating cell-free HMGA2 mRNA was amplified by real-time qRT-PCR from the plasma of 83 CRC patients prior to surgery and the plasma of 11 healthy volunteers. The detail clinical characteristics of the recruited patients are shown in Table 1 . Compared to healthy controls, statistically significant higher levels of circulating cell-free HMGA2 mRNA were observed in CRC patients (P < .001; Figure 1A ).
Subsequently, ROC curve analysis was performed to evaluate the diagnostic capabilities of circulating HMGA2 mRNA for CRC. As shown in Figure 1B , the AUC was 0.932 (95% CI, 0.882-0.983). And the best cutoff value was 0.044 which provided a sensitivity of 86.75% (95% CI, 77.5%-93.2%). More intriguingly, a strong positive correlation was found between plasma HMGA2 mRNA and CA199 levels (r = .380, P < .001; Figure 2 ). All these results demonstrated that circulating HMGA2 mRNA might function as a novel diagnostic marker for CRC.
| Plasma HMGA2 mRNA correlates with tumor location, nerve infiltration, vascular invasion, and MSI status
To further explore the role of HMGA2 in the progression of CRC, the association between plasma HMGA2 mRNA level and clinicopathologic parameters was evaluated. As shown in Table 1 , circulating HMGA2 mRNA levels were significantly correlated with tumor location, nerve infiltration, vascular invasion, MSI status, and serum CA199 levels. However, there was no difference between HMGA2 and other characteristics. As for tumor location, the patients with colon cancer (P = .006; Figure 3A ) and right-sided CRC (P = .011; Figure 3B ) showed higher levels of circulating cell-free HMGA2
mRNA. In addition, positive nerve infiltration (P = .004; Figure 3C ), positive vascular invasion (P = .048; Figure 3D ), negative MSI status (P = .022; Figure 3E ), or elevated serum CA199 levels (P = .022;
T Figure 3F ) significantly correlated with higher levels of plasma HMGA2 mRNA, suggesting that circulating HMGA2 mRNA increased with tumor progression.
| Circulating HMGA2 mRNA in plasma correlated with HMGA2 mRNA expression in tissues
To explore whether levels of HMGA2 mRNA in plasma were correlated with HMGA2 levels in tumors, real-time qRT-PCR analysis was employed for measurement of HMGA2 expressions in 54 primary colorectal cancer samples. Notably, levels of HMGA2 mRNA in plasma and HMGA2 protein in tumors were found to be strictly correlated (r = .767, P < .001, Figure 4 ).
| DISCUSSION
Accumulating studies have focused on cell-free nucleic acids (cfNAs)
as noninvasive biomarkers for diagnostic and prognostic purposes. 8, 9 The field of cfNAs in cancer has grown very fast in the past 20 years.
It is known that they originate from circulating tumor cells and increased levels of cfNAs (such as DNA, RNA, and miRNA) are significantly associated with tumor behaviors. [10] [11] [12] [13] Analyses of circulating cell-free nucleic acids can serve as "liquid biopsies" approaches, which
can be exploited for diagnosis in the early stages of cancer, assessment of prognosis, detection of recurrence, prediction of response to treatment, and identification of different genomic alterations during the course of treatment. 8, 12, 14, 15 cfNAs were first identified in human bloodstream in 1948 by Mandel et al. 16 Chan and co-workers conducted a prospective study and reported that circulating cell-free Epstein-Barr virus (EBV) DNA could be used for screening early asymptomatic nasopharyngeal carcinoma. 17 Body fluids are the main F I G U R E 1 Circulating HMGA2 mRNA expression is increased in the plasma of colorectal cancer (CRC) patients. (A) Dot plot analysis showed that higher levels of circulating cell-free HMGA2 mRNA were observed in CRC patients. Each dot represented as one case. The results were presented as mean ± SEM. ***P < .001. (B) ROC curves showed that plasma HMGA2 mRNA discriminated between CRC patients and healthy controls. The AUC of HMGA2 mRNA was 0.932. AUC, area under the curve; ROC, receiver operating characteristic F I G U R E 2 Correlation between HMGA2 mRNA and CA199 was shown in the dot plot. r = .380, P < .001 T A B L E 1 (Continued) sources for screening and detection of many noninvasive biomarkers, including sputum, saliva, and pleural effusion. 18, 19 However, the causes of the increase in cfNA during cancer development are still not well understood. Besides the cfDNA, circulating mRNA was also observed in the plasma of cancer patients. 20 Joosse and colleagues reported that the levels of circulating cell-free MAGE-A, BORIS mRNA, as well as let-7b were significantly increased in the patients with malignant breast carcinomas than in benign breast diseases. 21 Kim et al found that the urine levels of cell-free UBE2C RNA could differentiate between bladder cancer and hematuria, and it proved to be an independent indicator of prognosis. 22 In patients with breast cancer, cell-free mammaglobin and telomerase mRNAs could serve as useful cancer markers for diagnosis. 23, 24 Presence of cyclin D1 mRNA in plasma was associated with poor clinical outcome in a subset of patients with a good prognosis and it could be used as a marker of resistance to endocrine therapies. 25 Miura et al found that hTERT mRNA, combined with EGFR mRNA, was significantly elevated in the plasma of lung cancer patients, and might be useful to assess clinical stage. 26 In CRC, the presence of EGFR, CK19, CK20, REG4, uPA, and NPRL2 mRNA in peripheral blood could discriminate CRC from healthy controls, and furthermore, they were also correlated with cancer progression. 27 Thus, the applications of cfRNA-based assays enable the assessment of F I G U R E 3 Dot plot analysis showed that levels of circulating cell-free HMGA2 mRNA were correlated with tumor location (A and B), nerve infiltration (C), vascular invasion (D), microsatellite instability (MSI) status (E), and serum CA199 levels (F). The results were presented as mean ± SEM. *P < .05; **P < .01
Correlation between HMGA2 mRNA in plasma and HMGA2 mRNA expression in tissues was shown in the dot plot. r = .767, P < .001 cancers through gene expression profiling. Although they have a great potential, many problems must be tackled before proceeding to the clinic. 8, 14 Because of the low stability, high heterogeneity, and low occurrence frequencies of cfRNAs in plasma, one of the most important issues is the development and standardization of more powerful and reliable technologies. 8 It extends to each step in the process, including the blood collection procedure to improve the stability, cfRNAs extraction and quantification methods, and the approaches for detection of molecular and genetic alterations. With the rapid progress of technology, [28] [29] [30] [31] sensitivity and specificity have been greatly improved.
As an oncofetal protein, HMGA2 is highly expressed in a variety of neoplastic tissues, but low or absent in normal adult tissues. 32 However, there have been few studies focusing on the detection of circulating HMGA2 mRNA in blood. In breast cancer, expression of cell-free HMGA2 mRNA in plasma may serve as a powerful indicator for predicting worse prognosis. 33, 34 In their study of circulating HMGA2 in the peripheral blood of patients with epithelial ovarian cancer, Galdiero et al showed for the first time the expression of HMGA2
in the plasma of patients, instead of healthy donors. 35 In the present study, we found that patients with higher levels of circulating HMGA2
mRNA were more likely to be malignant. All these results demonstrated that circulating HMGA2 mRNA could serve as a potential biomarker for cancer diagnosis.
To our knowledge, this is the first study focusing on the detection of cell-free HMGA2 mRNA in the plasma of CRC patients. The level of circulating HMGA2 mRNA was found to be substantially higher in patients than in healthy volunteers. Our results demonstrated that HMGA2 gave a high diagnostic performance. Its expression was found to be significantly associated with tumor location, nerve infiltration, vascular invasion, MSI status, and serum CA199 levels. Levels of HMGA2 mRNA in plasma and HMGA2 mRNA in tissues were found to be strictly correlated. In summary, our study strongly indicated that cell-free HMGA2 mRNA in the plasma might act as a potential biomarker in the diagnostic prediction of CRC.
